J
Jodi J. Akin
Researcher at Edwards Lifesciences Corporation
Publications - 25
Citations - 20620
Jodi J. Akin is an academic researcher from Edwards Lifesciences Corporation. The author has contributed to research in topics: Valve replacement & Aortic valve replacement. The author has an hindex of 20, co-authored 25 publications receiving 18893 citations. Previous affiliations of Jodi J. Akin include Medical University of South Carolina & Brigham and Women's Hospital.
Papers
More filters
Journal ArticleDOI
Transcatheter Aortic-Valve Implantation for Aortic Stenosis in Patients Who Cannot Undergo Surgery
Martin B. Leon,Craig R. Smith,Michael J. Mack,D. Craig Miller,Jeffrey W. Moses,Lars G. Svensson,E. Murat Tuzcu,John G. Webb,Gregory P. Fontana,Raj Makkar,David L. Brown,Peter C. Block,Robert A. Guyton,Augusto D. Pichard,Joseph E. Bavaria,Howard C. Herrmann,Pamela S. Douglas,John L. Petersen,Jodi J. Akin,William N. Anderson,Duolao Wang,Stuart J. Pocock +21 more
TL;DR: In patients with severe aortic stenosis who were not suitable candidates for surgery, TAVI, as compared with standard therapy, significantly reduced the rates of death from any cause, the composite end point of deathFrom any cause or repeat hospitalization, and cardiac symptoms, despite the higher incidence of major strokes and major vascular events.
Journal ArticleDOI
Transcatheter versus Surgical Aortic-Valve Replacement in High-Risk Patients
Craig R. Smith,Martin B. Leon,Michael J. Mack,D. Craig Miller,Jeffrey W. Moses,Lars G. Svensson,E. Murat Tuzcu,John G. Webb,Gregory P. Fontana,Raj Makkar,Mathew R. Williams,Todd M. Dewey,Samir R. Kapadia,Vasilis Babaliaros,Vinod H. Thourani,Paul J. Corso,Augusto D. Pichard,Joseph E. Bavaria,Howard C. Herrmann,Jodi J. Akin,William N. Anderson,Duolao Wang,Stuart J. Pocock +22 more
TL;DR: In high-risk patients with severe aortic stenosis, transcatheter and surgical procedures for aorti-valve replacement were associated with similar rates of survival at 1 year, although there were important differences in periprocedural risks.
Journal ArticleDOI
Two-Year Outcomes after Transcatheter or Surgical Aortic-Valve Replacement
Susheel Kodali,Mathew R. Williams,Craig R. Smith,Lars G. Svensson,John G. Webb,Raj Makkar,Gregory P. Fontana,Todd M. Dewey,Vinod H. Thourani,Augusto D. Pichard,Michael P. Fischbein,Wilson Y. Szeto,Scott Lim,Kevin L. Greason,Paul S. Teirstein,S. Chris Malaisrie,Pamela S. Douglas,Rebecca T. Hahn,Brian Whisenant,Alan Zajarias,Duolao Wang,Jodi J. Akin,William N. Anderson,Martin B. Leon,Trial Investigators +24 more
TL;DR: A 2-year follow-up of patients in the PARTNER trial supports TAVR as an alternative to surgery in high-risk patients, but paravalvular regurgitation was more frequent after T AVR and was associated with increased late mortality.
Journal ArticleDOI
Transcatheter Versus Surgical Aortic-Valve Replacement in High-Risk Patients
Craig R. Smith,Martin B. Leon,Michael J. Mack,D. Craig Miller,Jeffrey W. Moses,Lars G. Svensson,E. Murat Tuzcu,John G. Webb,Gregory P. Fontana,Raj Makkar,Mathew William,Todd M. Dewey,Samir R. Kapadia,Vasilis Babaliaros,Vinod H. Thourani,Paul J. Corso,Augusto D. Pichard,Joseph E. Bavaria,Howard C. Herrmann,Jodi J. Akin,William N. Anderson,Duolao Wang,Stuart J. Pocock +22 more
Journal ArticleDOI
5-year outcomes of transcatheter aortic valve replacement or surgical aortic valve replacement for high surgical risk patients with aortic stenosis (PARTNER 1): a randomised controlled trial
Michael J. Mack,Martin B. Leon,Craig R. Smith,D. Craig Miller,Jeffrey W. Moses,E. Murat Tuzcu,John G. Webb,Pamela S. Douglas,William N. Anderson,Eugene H. Blackstone,Susheel Kodali,Raj Makkar,Gregory P. Fontana,Samir R. Kapadia,Joseph E. Bavaria,Rebecca T. Hahn,Vinod H. Thourani,Vasilis Babaliaros,Augusto D. Pichard,Howard C. Herrmann,David L. Brown,Mathew R. Williams,Michael J. Davidson,Lars G. Svensson,Jodi J. Akin +24 more
TL;DR: The findings show that TAVR as an alternative to surgery for patients with high surgical risk results in similar clinical outcomes.